Alatrash G - Search Results

1

Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor-positive Breast Cancer.

Goldberg J, Qiao N, Guerriero JL, Gross B, Meneksedag Y, Lu YF, Philips AV, Rahman T, Meric-Bernstam F, Roszik J, Chen K, Jeselsohn R, Tolaney SM, Peoples GE, Alatrash G, Mittendorf EA. Goldberg J, et al. Among authors: alatrash g. Cancer Res Commun. 2024 Feb 22;4(2):496-504. doi: 10.1158/2767-9764.CRC-23-0244. Cancer Res Commun. 2024. PMID: 38335301 Free PMC article.

2

Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion.

al-Atrash G, Kitson RP, Xue Y, Goldfarb RH. al-Atrash G, et al. In Vivo. 2000 Sep-Oct;14(5):565-70. In Vivo. 2000. PMID: 11125540

3

Rhabdomyolysis after ingestion of "foxy," a hallucinogenic tryptamine derivative.

Alatrash G, Majhail NS, Pile JC. Alatrash G, et al. Mayo Clin Proc. 2006 Apr;81(4):550-1. doi: 10.4065/81.4.550. Mayo Clin Proc. 2006. PMID: 16610577

4

Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.

Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM. Alatrash G, et al. J Clin Oncol. 2004 Jul 15;22(14):2891-900. doi: 10.1200/JCO.2004.10.045. J Clin Oncol. 2004. PMID: 15254058 Clinical Trial.

5

uPA and uPAR contribute to NK cell invasion through the extracellular matrix.

Al-Atrash G, Kitson RP, Xue Y, Mazar AP, Kim MH, Goldfarb RH. Al-Atrash G, et al. Anticancer Res. 2001 May-Jun;21(3B):1697-704. Anticancer Res. 2001. PMID: 11497249

6

Cyclic neutropenia associated with T cell immunity to granulocyte proteases and a double de novo mutation in GFI1, a transcriptional regulator of ELANE.

Armistead PM, Wieder E, Akande O, Alatrash G, Quintanilla K, Liang S, Molldrem J. Armistead PM, et al. Among authors: alatrash g. Br J Haematol. 2010 Sep;150(6):716-9. doi: 10.1111/j.1365-2141.2010.08274.x. Br J Haematol. 2010. PMID: 20560965 Free PMC article. No abstract available.

7

Targeting PR1 in myeloid leukemia.

Alatrash G, Molldrem JJ, Qazilbash MH. Alatrash G, et al. Oncotarget. 2017 Dec 18;9(4):4280-4281. doi: 10.18632/oncotarget.23403. eCollection 2018 Jan 12. Oncotarget. 2017. PMID: 29435102 Free PMC article. No abstract available.

8

A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin.

Goldfarb RH, Koelemij R, Muirhead KA, Ohlsson-Wilhelm BM, Gray BD, Kuppen PJ, Basse PH, al-Atrash G, Kitson RP. Goldfarb RH, et al. In Vivo. 2000 Jan-Feb;14(1):101-4. In Vivo. 2000. PMID: 10757065

9

Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.

Mittendorf EA, Alatrash G, Xiao H, Clifton GT, Murray JL, Peoples GE. Mittendorf EA, et al. Among authors: alatrash g. Expert Rev Vaccines. 2011 Jun;10(6):755-74. doi: 10.1586/erv.11.59. Expert Rev Vaccines. 2011. PMID: 21692698 Review.

10

The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.

Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, Wieder ED, Lizee G, Lu S, Molldrem JJ. Alatrash G, et al. J Immunother. 2012 May;35(4):309-20. doi: 10.1097/CJI.0b013e31824b3b14. J Immunother. 2012. PMID: 22495388 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

129 results

Search Page